This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad Genetics Study Highlights Importance Of MyRisk(TM) Hereditary Cancer Testing

SALT LAKE CITY, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data showing the high prevalence and overlap between hereditary colon cancer and hereditary breast and ovarian cancer in patients previously diagnosed with endometrial and ovarian cancer. Myriad is presenting this data and another hereditary cancer study at the 2013 National Society of Genetic Counselors annual meeting in Anaheim, California.

"Myriad is committed to advancing the scientific understanding of hereditary cancers and developing innovative diagnostic tests to benefit a broad range of cancer patients," said Richard J. Wenstrup, chief medical officer of Myriad. "Our data show there is both a high prevalence and overlap of hereditary cancer syndromes in patients with endometrial and ovarian cancers, which supports the use of myRisk Hereditary Cancer testing to accurately diagnose patients and select appropriate medical management."

Key data being presented at the NSGC annual meeting include:

Prevalence of Lynch Syndrome and HBOC among Patients with Primary Endometrial and Primary Ovarian Cancers [Raymond et al., Oct. 11, 2013 2:45 – 3:00 p.m.]

This study assessed the prevalence of hereditary colon cancer and hereditary breast and ovarian cancer in patients with both primary endometrial and ovarian cancer. Under current National Comprehensive Cancer Network guidelines these patients would meet the medical criteria for both hereditary breast and ovarian cancer testing and hereditary colon cancer testing. Results showed that among 1,529 patients evaluated, 11.2 percent had a deleterious mutation with 73.3 percent of the mutations in hereditary colon cancer genes and 26.7 percent in hereditary breast cancer genes. Although the prevalence of hereditary colon cancer was higher than hereditary breast cancer in patients with endometrial and ovarian cancers, these patients showed a strong family history overlap between the two syndromes. The findings suggest these patients would be appropriate candidates for testing with a hereditary cancer panel to prevent a missed diagnosis of hereditary cancer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.10 -0.56%
FB $118.15 0.08%
GOOG $698.21 0.36%
TSLA $213.88 -3.90%
YHOO $37.15 3.20%


Chart of I:DJI
DOW 17,700.50 +49.24 0.28%
S&P 500 2,053.78 +2.66 0.13%
NASDAQ 4,725.5250 -0.1140 -0.00%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs